Biotech giant Amgen received its third U.S. approval for a biosimilar Dec. 6, a competitor for Johnson & Johnson rheumatoid arthritis drug Remicade. Worldwide sales of Remicade have fallen 18 percent in the first nine months of 2019 to $3.35 billion, but still make up more than 10 percent of Johnson & Johnson’s pharmaceutical revenue.…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
